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Abstract
Background: Allergic rhinitis is an inflammatory disease of the upper airway mucosa that also
affects leukocytes in bone marrow and peripheral blood. Toll-like receptor 9 (TLR9) is a receptor
for unmethylated CpG dinucleotides found in bacterial and viral DNA. The present study was
designed to examine the expression of TLR9 in the nasal mucosa and in leukocytes derived from
different cellular compartments during symptomatic allergic rhinitis.
Methods: The study was based on 32 patients with seasonal allergic rhinitis and 18 healthy
subjects, serving as controls. Nasal biopsies were obtained before and after allergen challenge.
Bone marrow, peripheral blood and nasal lavage fluid were sampled outside and during pollen
season. The expression of TLR9 in tissues and cells was analyzed using immunohistochemistry and
flow cytometry, respectively.
Results: TLR9 was found in several cell types in the nasal mucosa and in different leukocyte
subpopulations derived from bone marrow, peripheral blood and nasal lavage fluid. The leukocyte
expression was generally higher in bone marrow than in peripheral blood, and not affected by
symptomatic allergic rhinitis.
Conclusion: The widespread expression of TLR9 in the nasal mucosa along with its rich
representation in leukocytes in different compartments, demonstrate the possibility for cells
involved in allergic airway inflammation to directly interact with bacterial and viral DNA.
Background
Allergic rhinitis is an inflammatory disorder of the
mucosa in the upper airways with infiltration of inflam-
matory cells like neutrophils, eosinophils, basophils and
mast cells [1]. Similar to other atopic diseases, it consti-
tutes a systemic condition where a local allergic reaction
may result in distant inflammatory manifestations [2-6].
Bacterial and viral infections are known to worsen allergic
rhinitis and induce exacerbations in asthma [7]. Although
the pathogenic mechanisms behind this have been exten-
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Toll-like receptors (TLRs) are a group of trans-membrane
receptors activated by conserved molecular patterns of
microbes [9]. Microbial ligands activate the innate
immune system to mount a defense response by binding
to TLRs and this process is suggested to be important for
an effective presentation of antigens to the adaptive
immune system [10]. Consequently, TLRs might be rele-
vant for the pathophysiology of inflammatory airway dis-
orders [11,12]. Ten different TLRs have been described in
humans and TLR9 is the receptor for unmethylated CpG
dinucleotides, found in bacterial and viral but not in
human DNA [13]. Expression of TLR9 has been demon-
strated on primary and cultured cells from the human
lower airway epithelium and in sinonasal tissue [14,15].
TLR9 has also been found on leukocytes like monocytes/
macrophages, B cells and neutrophils as well as in den-
dritic cells [16,17].
Data regarding the expression of TLRs during periods of
airway inflammation is scarce. We have recently demon-
strated that an intranasal allergen challenge increased the
expression of TLR2, TLR3 and TLR4 in nasal epithelial
cells [18]. Patients with vernal keratoconjunctivitis, a
chronic allergic inflammation of the ocular surface, have
been shown to exhibit reduced mRNA levels of TLR9 in
stromal cells [19], but the expression of TLR9 during aller-
gic airway inflammation remains to be explored. Hence,
the present study was designed to investigate the expres-
sion of TLR9 in human nasal mucosa and in leukocytes
derived from bone marrow, peripheral blood and nasal
lavage fluid, with focus on compartmental differences and
possible changes during symptomatic allergic rhinitis.
Methods
Subjects and study design
The study included 32 non-smoking patients (14 women
and 18 men) with birch and/or grass pollen induced sea-
sonal allergic rhinitis and 18 non-smoking healthy volun-
teers (10 women and 8 men), serving as controls. The
median (range) age of patients and controls was 27 (18–
54) and 26 (22–51) years, respectively. All control sub-
jects were healthy, as were the rhinitis patients with the
exception of their allergy.
The expression of TLR9 was assessed in nasal biopsies
using immunohistochemistry before and after allergen
challenge. Nasal biopsies were obtained from 11 patients
at two separate occasions outside pollen season. The first
biopsy was obtained during control conditions (outside
pollen season and without any prior allergen challenge).
2–4 weeks later, the same patients were challenged intra-
nasally with relevant pollen (birch or grass), and 24 hours
after this challenge a second biopsy was obtained from the
other nostril. The challenge was performed with 10,000
SQ/U per nostril of Aquagen (ALK, Denmark) with either
birch (3 patients) or grass pollen (8 patients). Nine con-
trols were sampled during the same period.
Flow cytometry analysis of TLR9 leukocyte expression was
performed on samples obtained during symptomatic
allergic rhinitis. Samples of bone marrow, peripheral
blood and nasal lavage fluid were obtained from 11
patients with symptomatic allergic rhinitis during either
the birch pollen (5 patients) or the grass pollen season (6
patients). They were included at the beginning of the pol-
len season after having experienced substantial symptoms
of rhino-conjunctivitis (itchy nose and eyes, sneezing,
nasal secretion and nasal blockage) during at least 3 con-
secutive days. The majority of patients were seen within
5–10 days after the first appearance of symptoms. A local
pollen count confirmed the presence of the relevant types
of pollen in the air during this period. In addition, 10
patients with allergic rhinitis and 9 healthy controls were
included outside pollen season.
The diagnosis of birch and grass pollen induced allergic
rhinitis was based on a positive history of seasonal allergic
rhinitis for at least 2 years and a positive skin prick test
(SPT) to birch and/or timothy pollen. Patients with sea-
sonal allergic rhinitis had experienced moderate to severe
symptoms previous pollen seasons [20,21]. SPT was per-
formed with a standard panel of 10 common airborne
allergens (ALK, Copenhagen, Denmark) including pollen
(birch, timothy and mugwort), house dust mites (D. Pter-
onyssimus and D. Farinae), molds (Cladosporium and Alter-
naria) and animal allergens (cat, dog and horse). It was
performed on the volar side of the forearm with saline
buffer as negative and histamine chloride (10 mg/ml) as
positive control. The diameter of the wheal reactions was
measured after 20 minutes. All patients presented a wheal
reaction diameter >3 mm towards birch or timothy in SPT
(roughly corresponding to a 3+ or 4+ reaction when com-
pared to histamine) [22]. Twelve patients presented posi-
tive reactions towards both birch and timothy and 8
patients were also positive for mugwort. Patients present-
ing positive reactions towards animals (8 towards cat, 6
towards dog and 3 towards horse), did not have any regu-
lar animal contact. The patients had no symptoms of
asthma at the time of visit and they did not take any regu-
lar asthma medication (short/long acting β-agonists or
inhaled steroids). Exclusion criteria included a history of
perennial symptoms, a history of upper airway infection
within 2 weeks before the visit and treatment with local or
systemic corticosteroids within 2 months before the visit.
The control subjects were symptom-free, had no history of
allergic rhinitis and had a negative SPT to the standard
panel of allergens described above. They had no history ofPage 2 of 13
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visit and they were all free of medication.
Before inclusion, all subjects, patients as well as controls,
were evaluated by an ear-, nose- and throat consultant
performing nasoscopy. Individuals with signs or symp-
toms of chronic rhinosinusitis, hypertrophy of turbinates,
severe septum deviation or nasal polyposis were excluded.
The study was reviewed and approved by the Ethics Com-
mittee of the Medical Faculty, Lund University, and
informed consent was obtained from all subjects.
Symptom and rhinoscopy scores
The subjects were asked to record the severity of three
nasal symptoms, i.e. itching/sneezing, secretion and
blockage using an arbitrary scale from 0 to 3 (0 = no, 1 =
mild, 2 = moderate, 3 = severe symptoms) at the time of
inclusion. A total nasal symptom score was calculated by
addition of the three scores. Patients challenged with
allergen were asked to record a change in this nasal symp-
tom score after 5 and 15 minutes. The maximum of this
symptom score was 9. Anterior rhinoscopy was performed
on individuals in this part of the study. Oedema and
secretion in each nostril were scored from 0 to 2 (0 = no,
1 = mild, 2 = severe). A total rhinoscopy score was calcu-
lated by adding the scores for each sign and each nostril.
The maximum rhinoscopy score was 8.
Nasal biopsy procedure
Biopsies were taken from the inferior turbinate after topi-
cal application of local anesthesia containing lidocainhy-
drochloride/nafazoline (34 mg/mL/0.17 mg/mL) for 20
minutes. Biopsies were obtained from 11 allergic patients
at two occasions (before and following allergen chal-
lenge), and from 9 healthy controls at one occasion.
Immunohistochemical analysis of TLR9
Nasal biopsies used for immunohistochemistry were fro-
zen in Tissue Tek® O.C.T mounting media (Histo Lab,
Gothenburg, Sweden) immediately after excision. Cryo-
sections, 8 µm thick, were after sectioning post-fixed with
2% buffered formaldehyde for 20 minutes, rinsed in
phosphate buffered saline (PBS; pH 7.6; 3 × 5 minutes) at
room temperature (RT) and placed in 0.1% saponin in
PBS for 20 minutes at RT. Non-specific binding sites were
blocked with 5% normal serum (DakoCytomation, Glos-
trup, Denmark; dilution 1:10 in PBS) for 30 minutes. Avi-
din-binding sites were blocked with incubation of Avidin
D solution (Vector Laboratories, Burlingame, CA, USA)
for 15 minutes. Thereafter, the sections were rinsed in PBS
(3 × 5 minutes) before blocking of biotin-binding sites
with biotin blocking solution (Vector Laboratories) for 15
minutes. After additional rinsing (PBS; 3 × 5 minutes) sec-
tions were incubated with the primary antibody overnight
at 4°C (in control sections the primary antibody was
omitted). The primary antibody was diluted in PBS sup-
plemented with 0.25% Triton X and 0.25% bovine serum
albumin. The primary antibody, anti-TLR9 (dilution
1:400) was purchased from ImmunoKontact, Oxon, UK.
After overnight incubation with primary antibody, the
sections were rinsed (3 × 5 minutes in PBS) and incubated
with biotinylated secondary antibody (horse anti-mouse
IgG1, dilution 1:200, Vector Laboratories) for 45 minutes
at RT. After additional rinsing (3 × 5 minutes in PBS), the
sections were incubated with alkaline phosphatase-
labeled streptavidin (dilution 1:200 for 45 minutes),
rinsed (3 × 5 minutes in PBS) and alkaline phosphate
activity was developed for 6 minutes at RT using New
Fuchsin (DakoCytomation) as enzyme substrate. Endog-
enous alkaline phosphatase activity was inhibited by
Levamisol. No unspecific staining was observed in control
sections where the primary antibody was omitted. In
additional control experiments, where an isotype-
matched antibody was used (M7894, Sigma, Saint Louis,
USA), no unspecific staining was found in the nasal epi-
thelium or submucosa. All sections were counter-stained
with Harris's hematoxylin, coated with Aqua Perm
mounting medium (484975 Life Sci. International), dried
overnight and mounted in DPX. Positive immunoreactiv-
ity was identified as a bright red precipitate. TLR9 immu-
noreactivity was assessed and documented by bright field
microscopy using an Olympus microscope (Olympus BX)
coupled to a high resolution digital camera (Olympus D-
50).
Bone marrow aspiration
One sample containing 1–2 ml of bone marrow was aspi-
rated from the posterior iliac crest following local anesthe-
sia with lidocainhydrochloride (10 mg/ml). The sample
was immediately placed in a culture medium containing
buffered tri-sodium citrate solution (0.129 M), RPMI
1640 with 2 mM HEPES and N-acetyl-L-alanyl-L-
glutamine (FG1233 Biochrom AG, Berlin, Germany).
Bone marrow aspiration was obtained from 7 patients
with symptomatic allergic rhinitis, from 9 allergic patients
outside pollen season and from 8 healthy controls.
Blood sample collection
One sample containing 4 ml of blood was collected in a
test tube containing EDTA (Vacuette® 454209) and ana-
lyzed for total leukocyte differential count on a cell coun-
ter (Beckman Coulter LH750, Marseille, France). An
additional sample containing 4 ml of blood was collected
in a test tube containing buffered tri-sodium citrate solu-
tion (0.129 M, BD Vacutainer™ 367704) and analyzed
with flow cytometry. Blood samples were obtained from
11 patients with symptomatic allergic rhinitis, from 10
allergic patients outside pollen season and from 9 healthy
controls.Page 3 of 13
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Nasal lavage fluid was obtained as previously described
[23]. Briefly, after clearing excess mucous by forceful
exsufflation, 8–10 ml of sterile saline solution (0.9%
NaCl) of RT was aerosolized into each nostril, while clear-
ing the other. The nasal fluid was allowed to return pas-
sively and collected in a graded test tube, until 7 ml were
recovered. The fluids were centrifuged for 10 minutes at
1334 g and 4°C. The pellet, containing the cells, was dis-
solved in buffered tri-sodium citrate solution (0.129 M)
before analysis with flow cytometry. Nasal lavage fluid
was obtained from 11 patients with symptomatic allergic
rhinitis, from 8 allergic patients outside pollen season and
from 8 healthy controls.
Flow cytometry of leukocytes in bone marrow, peripheral 
blood and nasal lavage fluid
Bone marrow and nasal lavage samples were filtrated
prior to preparation. Analysis was performed for both
extracellular (cell membrane) and intracellular occurrence
of TLR9. All samples were labeled with CD16-Pcy5
(IM2642, Immunotech, Marseille, France) and CD45-
ECD (IM2710, Immunotech) for 15 minutes at RT. For
extracellular staining, cells were labeled with TLR9-FITC
(211MG3TLR9, ImmunoKontact) for 15 minutes at RT.
Erythrocytes in a 50 µl sample were lysed by mixing with
0.6 ml 0.1% (v/v) formic acid for 3–4 seconds. The ionic
strength was rendered iso-osmotic by addition of 0.28 ml
51 mM Na2CO3, 0.20 M Na2SO4 and 0.22 M NaCl, and
cells were washed in PBS and fixed in PBS containing 1%
formaldehyde prior to analysis. Intracellular staining was
performed using IntraPrep™ Permeabilization Reagent kit
(Immunotech) according to the specification of the man-
ufacturer. Thus, the cells were fixed and permeabilized
prior to incubation with TLR9-FITC for 15 minutes at RT.
Cells were washed in PBS and resuspended in PBS con-
taining 1% formaldehyde prior to analysis. In control
experiments (n = 6), cells were also incubated with isotype
control antibody, MsIgG1-FITC (PN IM0639, Immu-
notech).
By gating intact leukocytes on forward scatter (FSC) and
side scatter (SSC) properties as well as by their CD16 and
CD45 signals (Figure 1), leukocytes were separated into
neutrophils (R4 in Figure 1D), eosinophils (R8 in Figure
1C), basophils (R5 in Figure 1B), monocytes (R6 in Figure
1B) and lymphocytes (R7 in Figure 1B) [24,25]. In addi-
tion, immature granulocytes were gated in bone marrow
samples (R9 in Figure 1C) [26]. Neutrophil granulocytes
were the only cell type that could be clearly identified in
nasal lavage fluid. Mean fluorescence intensity ratio
(MFIR) was calculated by dividing the mean fluorescence
intensity (MFI) for TLR9 antibody with the MFI for the
negative control antibody (MsIg) [27,28]. Fluorescence
measurement was performed on a Coulter Epics XL flow
cytometer (Beckman Coulter). A total of 30,000 events
were collected in bone marrow and peripheral blood sam-
ples, and 3,000 events were collected in nasal lavage fluid.
Data were analyzed using Expo32 ADC analysis software
(Beckman Coulter).
An antibody towards a receptor for prostaglandin D2, the
chemoattractant receptor homologous molecule
expressed on Th2 (CRTH2), known to be highly expressed
on peripheral blood eosinophils and basophils [29], was
used to assess the purity of eosinophils and basophils.
Thus, peripheral blood leukocytes were stained in parallel
with CRTH2-PE (PN A07413, Beckman Coulter), CD16-
Pcy5 (IM2642, Immunotech) and CD45-ECD (IM2710,
Immunotech). Eosinophils and basophils were gated as
described above and their CRTH2 signal was examined. In
this way, the purity of the eosinophil and basophil gates
was determined to 98% and 76%, respectively. The purity
of monocytes was determined by staining peripheral
blood leukocytes in parallel with CD14-FITC (F0844,
DakoCytomation), CD16-PE (R7012, DakoCytomation)
and CD45-ECD (IM2710, Immunotech). Monocytes were
gated as described above and their CD14 signal was exam-
ined. The purity of the monocyte gate was determined to
85%. The purity of neutrophils was determined to 100%
with the use of the cell surface marker CD16-Pcy5
(IM2642, Immunotech).
Statistics
Statistical analysis was performed using the software
GraphPad Prism 4 (GraphPad Software, San Diego, USA).
All data are expressed as mean ± SEM, and n equals the
number of subjects. Kruskal-Wallis test was used in com-
bination with Dunn's Multiple Comparison Test to deter-
mine statistical differences. A p-value < 0.05 was
considered statistically significant.
Results
Symptom and rhinoscopy scores
Patients challenged with allergen reported augmented
nasal symptoms. The nasal symptom score increased with
1.3 ± 0.2 (p < 0.001) and 1.2 ± 0.2 (p < 0.001), after 5 and
15 minutes, respectively. Allergic patients examined dur-
ing pollen season, reported an increase in nasal and eye
symptom scores, 4.8 ± 0.6 and 3.9 ± 0.6, compared to
allergic patients examined outside season, 0.6 ± 0.3 (p <
0.001) and 0 (p < 0.001), as well as healthy controls, 0.6
± 0.2 (p < 0.001) and 0 (p < 0.001), respectively. In anal-
ogy, the rhinoscopy score in allergic patients was
increased during pollen season, 3.0 ± 0.6, in comparison
to allergic patients examined outside season, 1.1 ± 0.3 (p
< 0.05), and controls, 0.2 ± 0.1 (p < 0.001).Page 4 of 13
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Leukocyte gates on samples from bone marrow, peripheral blood and nasal lavage fluidFigure 1
Leukocyte gates on samples from bone marrow, peripheral blood and nasal lavage fluid. Flow cytometry data with 
dot plots showing gates for neutrophils, basophils, monocytes, lymphocytes, eosinophils and immature granulocytes in bone 
marrow, peripheral blood and nasal lavage fluid. Immature granulocytes were only found in bone marrow. In nasal lavage fluid 
only neutrophils could be clearly identified. A) FSC versus SSC with gate R1 representing nucleated leukocytes. B) CD45 ver-
sus SSC of cells gated from R1, representing basophils (R5), monocytes (R6) and lymphocytes (R7). C) CD45 versus CD16 of 
cells gated from R2, representing eosinophils (R8) and immature granulocytes (R9). D) FSC versus CD16 of cells gated from 
R3, representing neutrophils (R4).
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Respiratory Research 2007, 8:17 http://respiratory-research.com/content/8/1/17Immunohistochemical staining of TLR9 in the nose
Immunoreactivity for TLR9 was seen in many different
cell types within the epithelium and submucosa of the
nose (Figure 2). The distribution pattern of the epithelial
staining differed between subjects, in some subjects the
staining was foremost distributed to epithelial cells posi-
tioned in the apical region of the epithelium (Figure 2B),
whereas in others, the staining was equally distributed in
the whole epithelial layer (Figure 2C). Overall, the distri-
bution was similar between healthy controls and allergic
patients, and it was not changed by the allergen challenge.
A distinct TLR9 immunoreactivity was also found in the
endothelial cells lining small venules and capillaries (Fig-
ure 2D) and in subepithelial structural cells, tentatively
identified as fibroblasts (Figure 2C). Immunoreactivity
for TLR9 was also seen in scattered intraepithelial and sub-
epithelial leukocytes (Figure 2C). The identification of
these cells was based on morphological criteria and in this
regard, mast cells were identified as large granulated
mononuclear cells, macrophages and dendritic cells as
large agranular mononuclear cells, granulocytes by their
characteristic polymorph nuclei and lymphocytes as small
mononuclear cells with a circular nucleus surrounded by
only a thin rim of cytoplasm. Using these morphological
criteria, TLR9 immunoreactivity was identified in mast
cells (inset Figure 2E), dendritic cells (Figure 2E), granulo-
cytes and lymphocytes (Figure 2E–F). There was no differ-
ence in the expression of leukocyte-associated TLR9
between healthy controls and allergic patients, and an
altered expression could not be detected after the allergen
challenge.
Total leukocyte counts and cell distributions in peripheral 
blood and bone marrow
Total leukocyte counts in peripheral blood were similar
among the three groups, 6.0 ± 0.4 × 106 cells/ml in con-
trols, 5.3 ± 0.4 × 106 cells/ml in allergic patients outside
pollen season and 6.5 ± 0.4 × 106 cells/ml in allergic
patients during season. The proportion of neutrophils,
eosinophils, basophils, monocytes, and lymphocytes in
peripheral blood and bone marrow, and the percentage of
immature granulocytes in bone marrow did not differ
between the three groups (data not shown).
Leukocyte expression of TLR9 in bone marrow, peripheral 
blood and nasal lavage fluid
In bone marrow, an intracellular expression of TLR9 was
found in neutrophils, eosinophils, basophils, monocytes,
lymphocytes and immature granulocytes (Figure 3). No
extracellular expression was found on bone marrow leu-
kocytes. In peripheral blood, a similar intracellular expres-
sion of TLR9 was found in neutrophils, eosinophils,
basophils, monocytes and lymphocytes (Figure 3). A low
extracellular expression was found on monocytes (data
not shown). Neutrophils were the only cell type that
could be clearly identified by flow cytometry analysis in
nasal lavage fluid. The number of cells found in nasal lav-
age fluid varied considerably between individuals, and
generally fluids sampled during pollen season yielded the
highest cell content. Intracellular expression of TLR9 was
evident in neutrophils in nasal lavage fluid (Figure 3).
Mean fluorescence intensity ratio of TLR9 in different 
compartments and cell types
First, the intracellular expression of TLR9, as measured by
MFIR, was compared between the different compartments
irrespective of the atopic status of the individuals from
which the cells were obtained. The intracellular expres-
sion of TLR9 in neutrophils was found to be higher in
bone marrow and nasal lavage fluid, 3.26 ± 0.33 and 3.98
± 0.38, respectively, compared to in peripheral blood,
2.24 ± 0.10 (p < 0.001 and p < 0.01, respectively; Figure
4A). The expression in eosinophils and basophils was
higher in bone marrow, 5.24 ± 0.43 and 3.31 ± 0.23, com-
pared to in peripheral blood, 2.64 ± 0.18 and 1.99 ± 0.12,
respectively (p < 0.001, Figure 4B–C). There was no differ-
ence in the expression of TLR9 in monocytes and lym-
phocytes in bone marrow, 6.85 ± 0.88 and 3.46 ± 0.36,
compared to peripheral blood, 5.14 ± 0.65 and 3.34 ±
0.27, respectively (Figure 4D–E).
Next, the influence of allergic inflammation on the leuko-
cyte expression of TLR9 was examined. The levels of intra-
cellular TLR9 expression, as determined by MFIR, were
compared between healthy controls, allergic patients out-
side pollen season and patients during season in each cell
type (Figure 5A–C). The expression of TLR9 in peripheral
blood monocytes was lower in patients during pollen sea-
son, 3.56 ± 0.27, compared to patients outside season,
7.70 ± 1.53 (p < 0.01, Figure 5B).
Discussion
A distinct expression of TLR9 was found in the epithe-
lium, in inflammatory cells in the submucosa, in the
endothelial lining and in structural cells in the nose. TLR9
expression could also be demonstrated in permeabilized
neutrophils, eosinophils, basophils, monocytes, lym-
phocytes and immature granulocytes derived from bone
marrow, peripheral blood and nasal lavage fluid. Neu-
trophils, eosinophils and basophils had a higher expres-
sion of TLR9 in bone marrow than in peripheral blood.
The onset of symptomatic allergic rhinitis did not affect
the TLR9 expression in any of the compartments investi-
gated.
mRNA expression of TLR9 has been demonstrated in sino-
nasal tissue and expression of TLR9 mRNA and protein
has been reported in human cell lines and primary cells of
lower airway epithelium [14,15]. Expression of functional
TLR9 was detected in a study using a human bronchialPage 6 of 13
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TLR9 immunoreactivity in the nasal mucosaFigure 2
TLR9 immunoreactivity in the nasal mucosa. Immunohistochemical localization of TLR9 in biopsies of nasal mucosa is 
depicted in (B-F) whereas (A) illustrates a representative picture of a control slide. A) No immunoreactivity was observed in 
control sections where an isotype-matched control antibody was used. B) In an adjacent section, immunoreactivity for TLR9 is 
seen in the apical part of the epithelial lining, in scattered intra- and subepithelial leukocytes and in elongated fibroblast-like 
cells in the subepithelial tissue (arrow). The epithelial TLR9 immunoreactivity varied from being foremost present within the 
apical region of the epithelium (B) to a more even distribution (C). D) A distinct TLR9 immunoreactivity was also present in 
endothelial cells (arrowhead). E) Bright field micrographs demonstrating TLR9-positive large non-granulated mononuclear cells 
(arrowhead) and mast cells (inset). F) TLR9-positive intraepithelial lymphocytes (arrows E-F). Scale bars: A-C = 50 µm, D-E = 
20 µm, and F = 350 µm.
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Expression of TLR9 in leukocytes from bone marrow, peripheral blood and nasal lavage fluidFigure 3
Expression of TLR9 in leukocytes from bone marrow, peripheral blood and nasal lavage fluid. Histogram plots of 
intracellular staining of TLR9 in neutrophils, eosinophils, basophils, monocytes, lymphocytes and immature granulocytes. 
Expression of TLR9 in leukocytes was analyzed by flow cytometry using mAbs against human TLR9 (open histograms). Cells 
were fixed and permeabilized prior to incubation with mAbs. Shaded histograms represent cells labeled with isotype-matched 
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Expression of TLR9 in leukocytes in different compartmentsFigure 4
Expression of TLR9 in leukocytes in different compartments. Intracellular expression of TLR9, presented as MFIR, in 
bone marrow, peripheral blood and nasal lavage fluid. Expression of TLR9 in A) neutrophils (n = 23–28), B) eosinophils (n = 
23–29), C) basophils (n = 23–27), D) monocytes (n = 23–29) and E) lymphocytes (n = 23–29). Data are presented as mean ± 
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Expression of TLR9 in leukocytes during allergic rhinitisFigure 5
Expression of TLR9 in leukocytes during allergic rhinitis. Intracellular expression of TLR9, presented as MFIR, in differ-
ent leukocytes in healthy controls (C), allergic patients outside season (O) and allergic patients during pollen season (P). 
Expression of TLR9 in neutrophils, eosinophils, basophils, monocytes, lymphocytes and immature granulocytes analyzed by 
flow cytometry. Expression of TLR9 in leukocytes in A) bone marrow (n = 23), B) peripheral blood (n = 27–29) and C) nasal 
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TLR9 was found in the endothelial lining of small blood
vessels. This finding is in line with the detection of TLR9
mRNA in mouse lung endothelial cells [31]. Structural
cells, proposed to be fibroblasts, showed a variable
expression of TLR9 in accordance with a previous study
[19]. Expression of TLR9 was found in different inflam-
matory cells (i.e. leukocytes) in the epithelial and subepi-
thelial region. Based on morphological data, some of
these cells were identified as mast cells and dendritic cells.
Whereas expression of TLR9 has been demonstrated in
human peripheral blood-derived cultured mast cells
[32,33], mast cells in the conjunctiva did not stain for
TLR9 protein [19]. It is possible that the expression of
TLR9 in mast cells is variable in different localizations and
among different subtypes of mast cells. Immunohisto-
chemical analysis suggested an expression of TLR9 in
intra- and subepithelial lymphocytes and granulocytes.
In accordance with previous studies, we found a signifi-
cant intracellular expression of TLR9 in neutrophils and
eosinophils using flow cytometry [17,19,34]. In addition,
TLR9 was expressed in basophils, monocytes and lym-
phocytes. Only monocytes exhibited a low cell surface
expression of TLR9. This finding is in agreement with a
previous study where a minor proportion of freshly iso-
lated CD14+ monocytes and B-cells were shown to express
TLR9 on their cell surfaces [16]. Human tonsil B cells
express high amounts of TLR9 mRNA and protein as
determined by Western blot [35], which together with a
low surface staining indicate a predominantly intracellu-
lar expression of TLR9 in lymphocytes. Unstimulated
TLR9 is retained in the endoplasmatic reticulum [36] and
upon stimulation, it colocalizes with CpG oligodeoxynu-
cleotide (ODN) in a vesicular lysosomal compartment
where signaling is initiated [37]. Following CpG stimula-
tion, a minor portion of TLR9 becomes surface accessible
[37], and this might account for the low surface staining
found on monocytes in the present study [16]. Intracellu-
lar expression of TLR9 was found in bone marrow leuko-
cytes. Expression of TLR9 mRNA has been reported in
bone marrow-derived mast cells, plasmacytoid and myeo-
loid DCs [38], but to our knowledge, there are no previ-
ous studies that have demonstrated the expression of
TLR9 in human bone marrow leukocytes. In nasal lavage
fluid, neutrophils displayed an intracellular expression of
TLR9.
The expression of TLR9 in neutrophils, eosinophils and
basophils was higher in bone marrow compared to
peripheral blood. Such a difference was not seen in mono-
cytes and lymphocytes. Thus, it is possible that the expres-
sion of TLR9 has a role in the development and
differentiation of granulocytes. The high expression of
TLR9 in immature (CD16-negative) granulocytes in bone
marrow supports this view. It is also possible that the
bone marrow functions as a reservoir of granulocytes with
an increased expression of TLR9, ready to be discharged in
case of an infection. The nasal epithelium is constantly
exposed to the external environment with microbial com-
ponents and particles. This gives rise to a state of "physio-
logical inflammation" associated with a continuous
recruitment of neutrophils to the surface of the nasal
mucosa [39]. The increased expression of TLR9 in nasal
lavage fluid indicates either that neutrophils expressing
high levels of TLR9 are preferentially recruited to the nose
(via the bloodstream from the bone marrow reservoir), or
that neutrophils are primed with an increased expression
of TLR9 as they migrate towards the nasal lumen.
Previously, we reported an increased protein expression of
TLR2, TLR3 and TLR4 in the nasal epithelium following
allergen challenge [18]. In another study, expression of
TLR4 was upregulated and TLR9 downregulated in sub-
jects with vernal keratoconjunctivitis compared to healthy
controls [19]. In contrast to this, expression of TLR9 in the
nasal tissue was not affected by allergen challenge. In
analogy, we did not detect any differences in the leukocyte
expression of TLR9 during allergic airway inflammation in
bone marrow, peripheral blood or nasal lavage fluid. The
relevance of the decrease seen in the expression of TLR9 in
peripheral blood monocytes during pollen season is
uncertain, since this was not accompanied by a significant
decrease in the bone marrow. Even though we did not
find any differential expression of TLR9 in patients with
symptomatic allergic rhinitis, this does not exclude the
possibility that cells could influence the subsequent aller-
gic inflammation through TLR9. In murine models of
asthma and allergy, TLR9 stimulation with CpG during as
well as after the sensitization procedure, appears to
decrease the inflammatory process [40]. In analogy, CpG
has been reported to function as an adjuvant for immuno-
therapy in humans [41]. Thus, the distinct and general
expression of TLR9 in the nasal epithelium and in various
leukocytes in the nasal mucosa, indicates that bacterial
and viral airway infections might affect the adaptive
immune response directly by their content of CpG and
this could represent one pathogenic mechanism explain-
ing the worsening of allergic inflammation during airway
infections.
Conclusion
The widespread and rich expression of TLR9 in nasal epi-
thelial cells and on nearly all types of leukocytes derived
from bone marrow, peripheral blood and nasal lavage
fluid, indicates a broad opportunity for bacterial and viral
airway infections to interact directly with the adaptive
immune response via expression of CpG-related ligands.Page 11 of 13
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